Comparative performance characteristics of the urine lipoarabinomannan strip test and sputum smear microscopy in hospitalized HIV-infected patients with suspected tuberculosis in Harare, Zimbabwe by unknown
RESEARCH ARTICLE Open Access
Comparative performance characteristics of
the urine lipoarabinomannan strip test and
sputum smear microscopy in hospitalized
HIV-infected patients with suspected
tuberculosis in Harare, Zimbabwe
Lynn Sodai Zijenah1*, Gerard Kadzirange2, Tsitsi Bandason3, Maria Mary Chipiti1, Bevel Gwambiwa1,
Forget Makoga1, Pauline Chungu1, Philip Kaguru1 and Keertan Dheda4
Abstract
Background: In Zimbabwe, sputum smear microscopy (SSM) is the routinely used TB diagnostic tool in hospitalised
HIV-infected patients. However, SSM has poor sensitivity in HIV-infected patients. We compared performance of
urine lipoarabinomannan strip test (LAM) and SSM among hospitalized HIV-infected patients with suspected TB.
Methods: Hospitalized HIV-infected patients with suspected TB were randomized to LAM plus SSM or SSM alone
groups as part of a larger multi-country parent study. Here we present a comparison of LAM versus SSM performance
from the Zimbabwe study site. LAM analyses (grade 2 cut-off) were conducted using (i) a microbiological reference
standard (MRS; culture positivity for M.tb and designated definite TB) and (ii) a composite reference standard (CRS;
definite TB plus probable TB i.e. patients with clinical TB excluded from the culture negative group). CRS constituted
the primary analysis.
Results: 82/457 (18 %) of the patients randomized to the LAM group were M.tuberculosis culture positive. Using CRS,
sensitivity (%, 95 % CI) of LAM was significantly higher than SSM [49.2 (42.1-56.4) versus 29.4(23.2-36.3); p < 0.001].
Specificity and PPV were 98.1 %, and 95.8 %, respectively. By contrast, using MRS, LAM sensitivity was similar to SSM
and specificity was significantly lower, however, the combined sensitivity of LAM and SSM was significantly higher than
that of SSM alone, p = 0.009. Using CRS, LAM sensitivity (%, CI) was CD4 count dependent [60.6(50.7-69.8) at ≤50 cells/
μL; 40.0(22.7-59.4) at 51-100 cells/μL, and 32.8(21.0-46.3) at >100 cells/μL. The combined sensitivity of LAM and SSM
was higher than SSM alone being highest at CD4 counts <50 cells/μL [67.6(57.9-76.3); p = <0.001]. Specificity of LAM or
SSM alone, or of combined LAM and SSM was >97 % in all the 3 CD4 strata.
Conclusion: Among hospitalized HIV-infected patients with suspected TB, the sensitivity of LAM is significantly higher
than that of SSM, especially at low CD4 counts. LAM and SSM are complimentary tests for diagnosis of TB in HIV-
infected patients. We recommend a combination of LAM and SSM for TB diagnosis in HIV-infected patients with low
CD4 counts in HIV/TB co-endemic countries, where alternative methods are unavailable.
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Background
Tuberculosis (TB) is the major cause of morbidity and
mortality among HIV-infected patients in southern
Africa which bears 80 % of the global HIV burden
[1]. Sputum smear microscopy (SSM), the routinely
used microbiological TB diagnostic tool in Zimbabwe,
has poor sensitivity (20–50 %) identifying only a mi-
nority of HIV/TB co-infected patients [2]. The ability
of SSM to identify patients with TB may rely on the
patient’s ability to produce “quality sputum”. Studies
have shown that HIV infected patients are not able to
produce “quality sputum” or produce paucibacillary
sputum resulting in possibly false negative microscopy
results [3].
Alere has developed a point of care (POC) lateral flow
urine Lipoarabinomannan strip test (LAM) which has
been evaluated in various countries [4–10] with widely
varying performance characteristics. The current con-
sensus is that the test is most suitable for HIV-infected
patients with CD4 counts <200 cells/μl [11]. However,
there is lack of clarity about the context in which LAM
testing should be used. In the current study we aimed to
compare the performance characteristics of the LAM
and SSM among hospitalized HIV-infected patients
using culture as the reference standard.
Methods
Ethical approval
The study was approved by the Medical Research Council
of Zimbabwe (MRCZ/A/1680). All participants gave their
written informed consents.
Study design and study participants
The original study was a multi-centric randomized con-
trolled trial (RCT) registered with Clinicaltrials.gov
number:NCT01770730.
In the RCT, hospitalized HIV-infected patients with
suspected TB were randomized to LAM group where,
LAM, SSM, chest x-ray and culture were performed or
no LAM group, where SSM, chest x-ray and culture
were performed, using a computer generated allocation
list. Patients were followed-up at 2 months. We analysed
data from patients randomized to the LAM group only
where both LAM and SSM were performed on the same
patient. Participants’ demographics medical examina-
tions, TB symptoms were recorded.
At enrolment, at least two sputum specimens were
collected from each participant for same day micros-
copy. One sputum specimen was submitted for culture
and a third sample if available was stored at -80 °C.
Blood was collected for HIV testing and CD4 count.
Spot urine was collected for LAM.
Bacteriological testing
SSM using a fluorescence microscope was done with
auramine stain for screening and confirmation of aura-
mine positive smear was with Ziel-Neelsen (Z-N) stain.
LAM was performed by a State certified laboratory
technologist according to manufacturer’s instructions.
Briefly 60 μL of freshly collected urine was applied to
the test strip, incubated at room temperature for 25 min
and the result recorded as negative if there was no pres-
ence of any band or recorded as positive and band
graded as 1 or 2 or 3, 4 or 5 using the manufacturer’s
reference card with bands of graded intensity. The ana-
lysis was conducted using grade ≥2 cut-off, which has
been reported to have better inter-observer reliability
and good rule-in value in hospitalized patients [4]. How-
ever, it is important to note that the grade 2 cut-point
considered positive in this study using the pre-January
2014 reference card corresponds to the first positive
band (grade 1) in the current post-January 2014 refer-
ence card [12]. The Mycobacteria Growth Indicator
Tube (MGIT BD Microbiology Systems, Cockeysville,
MD, USA) culture was performed at a central laboratory
on sputum decontaminated using 4 % NaOH. Suspected
positive cultures were confirmed using Z-N staining.
MPT64 antigen detection was used for speciation of
MGIT positive cultures and by growth at different tem-
peratures if antigen detection was negative [13].
Definitions of the microbiological and composite
reference standards
MGIT which is routinely used as the reference TB diag-
nostic tool has limitations in HIV-infected patients par-
ticularly those with advanced Acquired Immunodeficiency
Syndrome (AIDS), low sputum bacillary load who are spu-
tum scarce. The following definitions were used to cat-
egorise patients into diagnostic groups based on smear
microscopy, culture and empirical treatment (radiological
findings and/or clinical symptoms) coupled with response
to treatment at the 2-months follow-up:
Definite TB
MGIT Mycobacterium Tuberculosis (MTB) positive.
Probable TB
MGIT MTB negative, a clinical and/or radiological find-
ing highly suggestive of active TB and supported by re-
sponse to anti-TB treatment at the 2-month follow-up.
Non-TB
No evidence of MTB and an alternative diagnosis made
and thus not treated for TB. Patients who were MTB
culture negative but were commenced on anti-TB treat-
ment empirically, yet showed no response to treatment
at the 2-months follow-up were also included in this
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group. Patients who were culture positive for non-
tuberculosis mycobacteria and were not receiving anti-
TB treatment were also included in this Non-TB group.
We conducted the comparative performance of LAM
using grade 2 cut cut-off positive results and SSM using
a (i) MRS (utilizing definite TB culture positive versus
culture negative) and (ii) CRS (utilizing definite TB plus
probable TB and patients with clinical TB excluded from
the culture negative group). Using the CRS, sensitivity
was calculated using the combined definite TB and
probable TB whilst the specificity calculations were
based on non-TB definitions
Data capture and analysis
The clinic and laboratory data was entered by two dedi-
cated data entry staff into a MS Access database. Epidata
software was used to validate dual entry of the data.
Demographic, clinical and microbiological characteris-
tics of different patient sub-groups were compared using
Chi-squared test and Wilcoxon rank-sum test as appro-
priate. For comparison of diagnostic tests results, MTB
species identification was used as reference standard for
culture positivity. Sensitivity, Specificity, Negative Pre-
dictive Value (NPV), Positive Predictive Value (PPV)
were calculated for all diagnostic tests (with 95 % confi-
dence intervals). All statistical tests were considered sig-
nificant at p = 0.05. STATA Version 12 (Stata Corp,
Texas, USA) was used for all statistical analyses.
Results
Patient recruitment
The flow chart of the study population is outlined in
Fig. 1. Of the 3128 hospitalized HIV-infected patients
screened, 920 with suspected TB were enrolled between
07 January 2013 and 26 September 2014 with 460 ran-
domly assigned to LAM and 460 to No LAM. Three out
of 460 (0.007 %) had invalid LAM results and were thus
excluded from the analysis. The baseline demographics
and clinical characteristics of the participants in the
LAM group based on TB diagnosis definition are shown
in Table 1. 82 /457 (18 %) had definite TB, 115/457
(25 %) had probable TB, 260/457 (57 %) were classified
as non-TB. The median CD4 count for non-TB, 71 cells/
μL, IQR: 24–180 was significantly lower than that of the
Fig. 1 Participants Flow. Flow chart of study participants and analysis. LAM= urine Lipoarabinomannan strip test; SSM = sputum smear microscopy
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combined definite TB; 41 cells/μL, IQR: 15-88 and prob-
able TB, 43 cells/μL, IQR: 17-128 groups; p < 0.0001.
The proportion of patients with fever was significantly
higher in the combined probable TB and definite TB
groups, p = 0.0001. A significantly higher proportion of
patients on anti-TB treatment with definite TB com-
bined with probable TB, reported improved TB symp-
toms at the 2-months follow-up when compared to the
non-TB patients, p = 0.003.
Comparative performance of SSM and LAM using MRS
Preliminary analysis showed that LAM grade ≥1 cut-off
had a significantly higher sensitivity 72.0 %, CI: 60.9–81.3
versus SSM 54.9 %, CI: 43.5-65.9; p = 0.022. However, the
specificity of LAM grade ≥1 cut-off was poor and signifi-
cantly lower, 74.7 %, CI: 69.9–79.0 vs 95.7. CI: 93.2–97.5;
p < 0.001. There was no significant difference in sensitivity
between LAM grade ≥1 cut-off; 72 %, CI: 60.9–81.3) vs
LAM grade ≥2 cut-off, 61 %, 49.6-71.6; p = 0.132. However,
the specificity of LAM grade ≥2 cut-off, 86.1 %, CI: 82.2–
89.5 vs LAM grade ≥1, 74.7 %, CI: 69.9–79.0; p < 0.001
was significantly higher.
All subsequent analysis reported in this study are
based on LAM grade ≥ 2 cut-off.
Of the 457 patients, 82/457 (18 %) were culture posi-
tive. Using the MRS, there was no significant difference
in sensitivity of LAM, 61.0 %, and SM; 54.9 %, p = 0.429
(Table 2). Specificity of SSM, 95.7 % was significantly
higher than that of LAM; 86.1 %, p < 0.001. Similarly the
PPV of SSM, 73.8 % was significantly higher than that of
LAM; 49.0 %, p = 0.007 (Table 2). However, there was no
significant difference in the NPV of SSM; 90.7 % and
LAM; 91.0 % p = 0.876.
The combined sensitivity of SSM and LAM, 74.4 %,
was significantly higher than that of SSM alone;
54.9 %, p = 0.009. Conversely, the combined specificity
was lower than that of SSM alone, 84.8 % versus
95.7 %, p < 0.001, so was the combined PPV; 51.7 %
Table 1 Demographics, clinical and microbiological characteristics of study patients stratified by TB diagnostic group
All Definite TB Probable TB Non-TB P-value
N = 457 N = 82 N = 115 N = 260
Demographics
Median age (IQR) 37 36 35 38 NS
(31-44) (32-41) (29-44) (31-45)
Female (%) 241 (53) 41 (50) 63 (55) 123 (52) NS
Median CD4 count (cells/μL, IQR) 55 41a 43 a 71* <0.0001
(18-153) (15-88) (17-128) (24-180)
Previous TB (%) 95 (21) 12(15) 26(23) 57(22) NS
Clinical features
Cough >2 wks (%) 446 (98) 82(100) 113(98) 251(97) NS
Drenching night sweats (%) 299 (65) 51(62) 81(70) 167(56) NS
Weight loss (%) 361 (79) 68(83) 92(80) 201(77) NS
Fever > 38 °C (%) 334 (73) 68 (82)a 90 (78)a 176(68)* <0.005
CXR compatible with TB (%) 252 (55) 61(74) 76(66) 115(44) <0.0001
Commenced on TB Treatment (%) 218 (48) 81(99)a 115(100)a 22(8)* <0.0001
TB treatment based on: n = 218 n = 81 n = 115 n = 22
Empirically (%) 87(40) 11(14)a 60(52)a 16(73)* <0.0001
LAM positive grades 1 and 2b 104b (48) 50(62)* 48(42)* 6(27)* <0.005
SSM 16(7) 11(14)* 5(4)* 0(0) <0.005
Culture 11(5) 9(11)* 2(2)* 0(0) <0.005
TB symptoms at 2 months for those on treatment n = 218 n = 81 n = 115 n = 22
Improved TB symptoms on treatment at 2 month follow-up 137(63) 54(66)* 83(72)* 0(0) 0.003
Died of TB before 2 months follow-up 61(28) 19(23)a 32(28)a 10(45) 0.023
Lost to follow-up on treatment 2(1) 1(1) 0(0) 1(5) NS
CXR Chest x-ray, LAM urine Lipoarabinomannan strip test, SSM sputum smear microscopy
P-values indicate significant differences between patient groups (marked with * to indicate comparison group) for different patients characteristics
* - Significantly different (p ≤ 0.05). a - Significant difference after combining two groups
NS Not significant (p > 0.05). b102 patients had LAM ≥2 positivity and 2 had grade 1 and attending clinicians insisted on commencing anti-TB treatment for these
2 patients
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vs 73.8 %, p = 0.015. The combined NPV did not dif-
fer from that of either test alone, p > 0.05 (Table 2).
Comparative performance of SSM and LAM using CRS
In sharp contrast to MRS-based analysis, when the CRS
was employed, the sensitivity of LAM, 49.2 % was sig-
nificantly higher than that of SSM, 29.4 %; p < 0.001.
The PPV for LAM and SSM (95.1 %) were similar, p =
0.996. However the NPV of LAM 71.8 % was signifi-
cantly higher than that of SSM, 64.9 %; p = 0.042
(Table 3).
The sensitivity of SSM combined with LAM was signifi-
cantly higher than that of SSM alone 57.4.8 %; p < 0.001.
However there was no significant difference in combined
specificity (>98 %), p > 0.05, nor PPV (>95 %); p > 0.05.
The NVP of SSM combined with LAM was significantly
higher (75.2 %0; p < 0.001 than SSM alone. (Table 3).
Comparative performance of LAM and SSM stratified by
CD4 count using MRS
The sensitivity of LAM versus SSM was not significantly
different at CD4 counts: ≤50 cells/μL; 51-100 cells/μL
and >100 cells/μL (Table 4). Specificity of SSM was sig-
nificantly higher at all the three CD4 count strata com-
pared to LAM (Table 4).
When combined, the sensitivity of SSM and LAM was
highest at CD4 count ≤50 cells/μL and was significant
higher than that of SSM alone; 87.2 %, CI: 74.3-95.2 p =
0.008. The specificity at the two CD4 count strata (≤50
cells/μL and >100 cells/ μL) for the combined SSM and
LAM was significantly lower for SSM (Table 4).
Table 2 Comparative performance of SSM versus LAM, and the combination of LAM and SSM versus SSM alone using the
microbiological reference standard
SSM versus LAM Combined SSM and LAM versus SSM alone
N = 457 SSM only LAM only p-value SSM only LAM only SSM plus LAM p-value
Sensitivity 54.9 % 61.0 % 0.429 54.9 %* 61.0 % 74.4 %* 0.009
(95 % CI) (43.5–65.9) (49.6-71.6) (43.5-65.9) (49.6–71.6) (63.6-83.4)
n + ve/total 45/82 50/82 45/82 50/82 61/825
Specificity 95.7 % 86.1 % <0.001 95.7 %* 86.1 % 84.8 %* <0.001
(95 % CI) (93.2-97.5) (82.2-89.5) (93.2-97.5) (82.2-89.5) (80.8-88.3)
n -ve/total 359/375 323/375 359/375 323/375 318/375
PPV 73.8 % 49.0 0.007 73.8 %* 49.0 51.7 %* 0.015
(95 % CI) (60.9–84.2) (39.0-59.1) (60.9-84.2) (39.0–59.1) (42.3-61.0)
NPV 90.7 % 91.0 0.876 90.7 % 91.0 93.8 % >0.05
(95 % CI) (87.6-93.6) (87.5-93.8) (87.6–93.6) (87.5-93.8) (90.7-96.1)
SSM smear microscopy, LAM Urine Lipoarabinomannan strip test, n + ve number positive, n –ve number negative
P-value indicate significant differences between patient groups (marked with * and number to indicate comparison group) * - Significantly Different (p ≤ 0.05)
Table 3 Comparative performance of SSM versus LAM; and the combination of SSM and LAM versus SSM alone using composite
reference standard
SSM versus LAM Combined SSM and LAM versus SSM alone
N = 457 SSM only LAM only p-value SSM only LAM only SSM plus LAM p-value
Sensitivity 29.4 % 49.2 % <0.001 29.4 %* 49.2 % 57.4 % * <0.001
(95 % CI) (23.2-36.3) (42.1-56.4) (23.2-36.3) (42.1-56.4) (50.1-64.4)
n + ve/total 58/197 97/197 58/197 97/197 113/197
Specificity 98.8 % 98.1 % 0.476 98.8 % 98.1 % 98.1 % >0.05
(95 % CI) (96.7-99.8) (95.6-99.4) (96.7-99.8) (95.6-99.4) (95.6-99.4)
n -ve/total 257/260 255/260 255/260 255/260 255/260
PPV 95.1 % 95.1 % 0.996 95.1 % 95.1 % 95.8 % >0.05
(95 % CI) (86.3-99.0) (88.9-98.4) (86.3-99.0) (88.9–98.4) (90.4-98.6)
NPV 64.9 % 71.8 % 0.042 64.9 %* 71.8 % 75.2 %* <0.001
(95 % CI) (60.0-69.6) (66.8–76.5) (60.0-69.6) (66.8-76.5) (70.3-79.7)
SSM sputum smear microscopy, LAM urine Lipoarabinomannan strip test, n + ve number positive, n –ve number negative
P-value indicate significant differences between patient groups (marked with * and number to indicate comparison group) * - Significantly different (p ≤ 0.05)
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Comparative performance of LAM and SSM stratified by
CD4 count using CRS
The sensitivity of LAM was significantly higher at CD4
count ≤50 cells/μL; 60.6, 95 % CI: 50.7–69.8 versus SSM;
35.8, 95 % CI: 26.8–45.5, p < 0.001 (Table 5, Fig. 2).
There was no significant difference in sensitivity at CD4
counts 51–100 cells/μL, p = 0.417. The specificity of
SSM and LAM was not significantly different at the
three CD4 counts strata (Table 5).
The combined sensitivity; 67.6 %, CI: 57.9–76.3 of LAM
and SSM was significantly higher than that of SSM alone,
being highest at ≤50 cells/μL, p < 0.001 (Fig. 2). The com-
bined specificity of LAM and SSM >97 % at the three
CD4 strata (Table 5) was not significantly different from
that of either test alone.
Discussion
To our knowledge, this is the first study in Zimbabwe to
compare the performance characteristics of LAM with
the routinely used SSM among hospitalized, HIV-
infected patients with suspected TB. Our study had
some interesting findings. First, employing the CRS
(used as the primary analysis in this case because of
sampling bias when using the MRS) we have shown that
LAM is more sensitive than SSM and the combination
is better than either diagnostic modality alone. More-
over, specificity was excellent. Secondly, when stratified
by CD4 count, the sensitivity of LAM is highest at CD4
count ≤50 cells/μl. Similarly the sensitivity of the com-
bined tests is highest at CD4 counts ≤50 cells/μL identi-
fying 87 % TB-infected patients. Indeed, in Zimbabwe
Table 4 Comparative performance of SSM versus LAM; and the combination of SSM and LAM versus SSM alone using the
microbiological reference standard, stratified by CD4 count
N = 457 SSM versus LAM Combined SSM with LAM versus SSM alone
SSM only LAM only p-value SSM only LAM only SSM plus LAM p-value
Sensitivity (95 % CI)
CD4 (cells/μL)
≤50 63.8 (48.5-77.3) 76.6 (62.0-87.7) 0.176 63.8 (48.5-77.3)* 76.6 (62.0-87.7) 87.2 (74.3-95.2)* 0.008
51-100 50.0 (24.70- 75.3) 43.8 (19.8-70.1) 0.723 50.0 (24.70- 75.3) 43.8 (19.8-70.1) 62.5 (35.4-84.8) >0.05
>100 36.8 (16.3-61.6) 36.8 (16.3- 61.6) - 36.8 (16.3-61.6) 36.8 (16.3- 61.6) 52.6 (28.9-75.6) >0.05
Specificity (95 % CI)
CD4 (cells/μL)
≤50 93.0 (88.1-96.3) 80.7 (74.0-86.8) 0.001 93.0 (88.1-96.3)* 80.7 (74.0-86.8) 78.9 (72.1-84.8)* 0.001
51-100 98.4 (91.2-100.0) 90.2 (79.8-96.3) 0.052 98.4 (91.2-100.0) 90.2 (79.8-96.3) 90.2 (79.8-96.3) >0.05
>100 97.9 (94.0-99.6) 90.9 (85.0-95.1) 0.010 97.9 (94.0-99.6)* 90.9 (85.0-95.1) 89.5 (83.3-94.0)* 0.004
SSM sputum smear microscopy, LAM Urine Lipoarabinomannan strip test
P-value indicate significant differences between patient groups (marked with * and number to indicate comparison group) * - Significantly Different (p ≤ 0.05) NS – Not
Significantly Different (p > 0.05)
Table 5 Comparative performance of SSM versus LAM; and the combination of SSM and LAM versus SSM alone using composite
reference standard, stratified by CD4 count
N = 457 SSM versus LAM Combined SSM with LAM versus SSM alone
SSM only LAM only p-value SM only LAM only SM plus LAM p-value
Sensitivity (95 % CI)
CD4 (cells/μL)
≤50 35.8 (26.8-45.5) 60.6 (50.7-69.8) <0.001 35.8 (26.8-45.5)* 60.6 (50.7-69.8) 67.6 (57.9-76.3)* <0.001
51-100 30.0 (14.7-49.4) 40.0 (22.7-59.4) 0.417 30.0 (14.7-49.4) 40.0 (22.7-59.4) 50.0 (31.3-68.7) >0.05
>100 17.2 (8.6-29.4) 32.8 (21.0-46.3) 0.054 17.2 (8.6-29.4)* 32.8 (21.0-46.3) 41.4 (28.6-55.1)* 0.004
Specificity (95 % CI)
CD4 (cells/μL)
≤50 97.2 (92.2-99.4) 97.2 (92.2-99.4) >0.05 97.2 (92.2-99.4) 97.2 (92.2-99.4) 97.2 (92.2-99.4) >0.05
51-100 100.0 (92.5-100.0) 97.9 (88.7-99.9) >0.05 100.0 (92.5-100.0) 97.9 (88.7-99.9) 97.9 (88.7-99.9) >0.05
>100 100.0 (96.5-100.0) 99.0 (94.8-100.0) >0.05 100.0 (96.5-100.0) 99.0 (94.8-100.0) 99.0 (94.8-100.0) >0.05
SSM sputum smear microscopy, LAM Urine Lipoarabinomannan strip test
P-value indicate significant differences between patient groups (marked with * and number to indicate comparison group) * - Significantly different (p ≤ 0.05) NS-
Not significantly different (p > 0.05)
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AIDS patients with probable opportunistic infections,
such as TB, present late in the course of their disease at
tertiary hospitals as reflected by the low median CD4
counts (55cells/μL) in this study. The urgent need for a
rapid POC TB diagnostic tool for this group of patients
cannot be over-emphasized as they may benefit from
early commencement of anti-TB treatment. TB is the
major cause of morbidity and mortality among HIV-
infected patients [1]. SSM is the routinely used micro-
biological test for TB, yet it has poor sensitivity among
HIV-infected patients. Our study suggests additional
benefit of a rapid POC TB diagnostic tool which utilizes
easily obtainable urine and produces results within
30 min.
The specificity of LAM (86 %), using MRS in our study
is below the usual acceptable level of 95 % or more for ac-
ceptability of any new diagnostic test. Several reasons may
be attributable to the low specificity. The reference stand-
ard culture, which uses sputum is inappropriate. It is
widely known that HIV-infected patients are often sputum
scarce or have paucibacillary sputa and hence do not pro-
duce “good quality” sputum, thus likely contributing to
false negative culture results. To address this issue, and
where sampling error is high, we opted to use the CRS
that is likely more appropriate in this specific context. The
specificity of LAM was significantly improved from 86 %
to 98 % when using the CRS. Similarly the PPV of LAM
was also greatly improved from a mere 49 % to 95 %. We
agree that this introduces misclassification bias. However,
this specificity is likely to be more accurate than that that
obtained using MRS due to the dominating effect of sam-
pling bias (significant possibility of false negative culture
results). Nevertheless, we present both analytical strategies
so the relative differences can be appreciated.
Based on the sensitivity of LAM, which was signifi-
cantly higher than that of the routinely used SSM; the
higher sensitivity of SSM and LAM combination than
SSM alone and the high specificity and PPV of LAM
when using the CRS, a combination of LAM and SSM
offers a very attractive option for diagnosis of HIV-
associated TB in hospitalized patients who are heavily
immunosuppressed. LAM has the added advantages of
using urine which is easily and rapidly obtained even
from very ill patients compared to sputum. It is an easy
to use POC test which can also be performed by trained
nurses making it an ideal POC test [7]. It does not require
electricity or any equipment, making it ideal for rural areas
where the majority of patients live in resource-limited
countries. Each LAM test costs less than US$3.50 [4].
Moreover, adding LAM to routine TB diagnostic work-up
among HIV-infected adults with CD4 counts <100 cell/μL
has been reported to be cost-effective [5].
The LAM has been evaluated globally but with widely
varying sensitivity (13 % to 93 %) and specificity (87 % to
99 %) (reviewed in [11]). The variability may be attrib-
uted to the study design, study populations, hospitalized
versus out-patients, HIV status, degree of immunosup-
pression as assessed by CD4 counts, use of fresh urine
versus frozen urine, cut-off grade for positive result
(grade 1 versus grade 2), and performance of the test by
state certified technologist versus trained nurses etc.
These variations make it difficult to compare perform-
ance characteristic of LAM across various settings. How-
ever, in the majority of the studies which stratified
Fig. 2 Comparative sensitivity of SSM versus LAM; and the combination of SSM and LAM versus SSM alone using composite reference standard
stratified by CD4 counts. SSM; sputum smear microscopy; LAM; urine Lipoarabinomannan strip test. a P-value indicates significant differences
between SSM only and LAM only. bP-value indicates significant differences between SSM only and SSM plus LAM
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performance of LAM by CD4 counts, the consensus is
that sensitivity of LAM was highest in patients with low
CD4 counts (reviewed in [11]). Our study lends support
to the growing consensus.
To our knowledge, only two other studies, one in
South Africa [4] and another in Uganda [9] have evalu-
ated LAM in hospitalized HIV-infected patients with
suspected TB. The South African study [4] like our
current study used both MRS and CRS for LAM grade 2
cut-point analysis. Comparison of LAM performance
characteristics is not possible due to the different study
designs and degree of immunosuppression. Furthermore
the South African study used frozen urine whereas in
the current study, spot fresh urine was used. However,
the two studies (South Africa and Zimbabwe) showed
that using the CRS the specificity of LAM was high
(>95 %). The two studies also showed that combining
LAM and SSM significantly increased the sensitivity.
The Ugandan study [9] used a MRS based LAM grade 2
cut-off analysis. Based on the overlapping CI, the sensi-
tivity in our study 61 %, CI: 49.6–71.6 was similar to that
in the Ugandan study; 49 %, CI: 39.0–59.0. Conversely,
the specificity of LAM was higher in the Ugandan study
97 %, CI: 92.0–99.0 versus 86 %, CI: 82.2–89.5. The dif-
ferences in specificity between the two studies (Uganda
and Zimbabwe) may be attributable to misclassification
bias and differences in study design (case controlled ver-
sus unselected cohort design).
There are some limitations of our study. We did
not perform Gene Xpert, which has been partly rolled
out in several countries. Thus, comparison of LAM
and Xpert was not possible. However, in most TB en-
demic countries globally and including Africa SSM is
still the predominant diagnostic modality. Thus, our
data have substantial relevance to clinical practice in
TB and HIV endemic settings. Misclassification bias
could have over or under estimated the accuracy of
LAM. The focus of this report is to highlight the per-
formance outcome of a combination diagnostic strat-
egy; patient important outcomes are reported
elsewhere (submitted).
Conclusion
Among hospitalized HIV-infected patients with sus-
pected TB, the combined sensitivity of SSM and LAM,
using CRS, is significantly higher than that of SSM, espe-
cially at low CD4 counts. The specificity is greater than
95 % for either test alone or combined. Thus, LAM and
SSM are complimentary tests for diagnosis of TB in
HIV-infected patients. We recommend a combination of
LAM and SSM for TB diagnosis in HIV-infected pa-
tients with low CD4 counts in HIV/TB co-endemic
countries, where alternative methods are unavailable.
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